- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P4 trial: Fiasp (clinicaltrials.gov) - Nov 3, 2019 P4, N=25, Not yet recruiting,
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - Oct 15, 2019 P=N/A, N=323, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| ultra-rapid acting insulin (AT247) / Arecor
Trial completion: AT247, NovoRapid (clinicaltrials.gov) - Sep 29, 2019 P1, N=18, Completed, Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Trial primary completion date: Evaluation of Fiasp (clinicaltrials.gov) - Sep 19, 2019 P4, N=20, Completed, Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Mar 2019
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) - Sep 4, 2019 P2/3, N=36, Completed, Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Mar 2019 N=56 --> 36
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Sep 3, 2019 P1, N=24, Completed, N=56 --> 36 Recruiting --> Completed | Trial completion date: Sep 2019 --> Apr 2019 | Trial primary completion date: Sep 2019 --> Apr 2019
- |||||||||| NovoLog (insulin aspart) / Novo Nordisk
Journal: Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? (Pubmed Central) - Aug 28, 2019 Unexplained hyperglycemia and premature infusion set changes were more common with FIASP than with insulin aspart. This study demonstrated sufficient safety and efficacy of FIASP in the pump setting to pave the way for longer, larger and more definitive clinical trials.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Journal: Insulins for type 2 diabetes. (Pubmed Central) - Aug 6, 2019 This study demonstrated sufficient safety and efficacy of FIASP in the pump setting to pave the way for longer, larger and more definitive clinical trials. No abstract available
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date, Real-world evidence, Real-world: Effect of Fiasp (clinicaltrials.gov) - Jun 25, 2019 P=N/A, N=244, Not yet recruiting, Initiation date: Jul 2019 --> Oct 2019 Trial completion date: Jun 2019 --> Oct 2019 | Initiation date: May 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Oct 2019
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: FIasp (clinicaltrials.gov) - Jun 5, 2019 P3, N=40, Recruiting,
- |||||||||| ultra-rapid acting insulin (AT247) / Arecor
New P1 trial: AT247, NovoRapid (clinicaltrials.gov) - May 21, 2019 P1, N=18, Recruiting,
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - May 16, 2019 P=N/A, N=326, Active, not recruiting, Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New trial, Real-world evidence, Real-world: Effect of Fiasp (clinicaltrials.gov) - Mar 29, 2019 P, N=244, Not yet recruiting,
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment change, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - Feb 15, 2019 P=N/A, N=440, Enrolling by invitation, Not yet recruiting --> Recruiting N=686 --> 440
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - Feb 4, 2019 P=N/A, N=686, Enrolling by invitation, Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Aug 2019
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date: Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 31, 2019 P4, N=40, Not yet recruiting, Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Aug 2019 Trial completion date: Oct 2020 --> Feb 2021 | Initiation date: Oct 2018 --> Feb 2019 | Trial primary completion date: Oct 2020 --> Feb 2021
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) - Nov 27, 2018 P2/3, N=56, Completed, Initiation date: Oct 2018 --> May 2019 Active, not recruiting --> Completed
|